BioWorld

Jan. 22, 2010

Inspiration, Ipsen Try to Lock Up Hemophilia Market in $259M Deal

LONDON - Inspiration Pharmaceuticals Inc. and Ipsen SA are merging their hemophilia portfolios in a deal that will see Ipsen invest $259 million to fund clinical development of the two lead products, while Inspiration handles the work. (BioWorld Today) Read More

AMAG, InterMune Pump Up with Large Public Offerings

Global, Local Tracking Give Insights Into MRSA Spread

Elevation Pharma Hauls in $30M Series A to Fund COPD Studies

FDA Refuses to Approve SkyePharma Asthma Drug

BioNumerik Going for Survival in New Tavocept Phase III Trial

All Focus on Denufosol; Inspire's Prolacria Misses in Dry Eye Trial

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...